Celgene (CELG) 10-Q2008 Q1 Quarterly report

Filed: 12 May 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Acceleron, acquiree, allocated, allocation, alternative, AMRUBICINTM, AMRUBICINTMand, analog, analyzed, anthracyclin, approach, ARB, asset, assigned, assimilation, Australian, azacitidine, binding, biology, Biotech, breakdown, Building, Canadian, chargeback, chemotherapy, clarifying, comingled, comparison, compound, copy, corroborated, Dainippon, debilitating, dedicated, deductible, degree, depreciation, directly, dispersed, distant, diversion, DNA, East, EC, efficient, encouraged, enhance, enhanced, enlarge, Exhibit, exit, exiting, failure, flow, fluctuate, forma, gene, geographic, geographically, governmental, GPC, HDAC, hierarchy, high, hope, hypermethylation, identical, identifiable, illustrative, immunomodulation, independent, induction, ineligible, inhibition, institutional, intracellular, investee, involuntary, Japanese, lease, lending, located, longer, lung, manner, methodology, MethylGene, mix, month, negative, noncontrolling, noncurrent, nonrecurring, nucleoside, orphan, party, Pfizer, Pharmacia, Pharmion®in, poorly, practicable, prednisone, Preexisting, private, pro, proinflammatory, project, projected, properly, psoriatic, pyrimidine, reach, reacquired, recast, redundant, referenced, relocation, rescue, restructuring, retention, retrospective, reverse, roll, rolling, satraplatin, scientific, served, shown, signaling, size, source, Standard, stockholder, Sumitomo, superior, synthetic, TGA, tighter, track, transaction, trustee, turn, unadjusted, uniform, unobservable, unspecified, untreated, Upjohn, vidaza, Yen, York, Zufingen

Removed: Accumulated, adjustment, advantage, agent, ANDA, annually, application, attribute, backed, bifurcation, carcinoma, chain, collateral, collect, Committee, competing, consideration, construction, consumed, Cooperative, deficit, derecognition, differential, dilution, Director, disorder, Eastern, effectively, embedded, EMEA, enterprise, EntreMed, evaluate, FIN, FOCALINTM, found, FSP, funded, gain, generic, genomic, Group, health, healthcare, hold, human, hybrid, indefinite, instrument, Investigational, Japan, Jersey, label, large, launch, lenalidomide, leukemia, lymphocytic, MAA, medical, Medicinal, Miikana, mitigate, Monitoring, NASDAQ, Neuchatel, NPP, objective, obligation, ovary, palliative, patient, pomalidomide, preparation, presently, principally, professional, proteomic, purpose, randomized, reclassification, reclassified, recognizing, regulation, reimbursement, renovation, resolution, retained, retroactively, separately, short, sickle, site, spent, substantial, Summit, terminated, tissue, transfer, transition, treated, trial, uncertainty, unclear, utility, volatility, XRTM, Zofingen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CELG similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of Celgene Corporation (“the Company”) for the period ended March 31, 2008 (“the Periodic Report”), I, Sol J. Barer, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that the Periodic Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and that the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 12, 2008	/s/ Sol J. Barer
	Sol J. Barer
	Chief Executive Officer